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PEMBANGUNAN IMUNOESEI UNTUK MITRAGININ 
 
ABSTRAK 
  
Ketum merupakan tumbuhan tropika yang digunakan dalam perubatan 
traditional untuk mengurangkan kesakitan dan merawat cirit-birit. Walau 
bagaimanapun, di Malaysia, ketum seringkali disalahgunakan sebagai dadah rekreasi 
disebabkan kesan rangsangan sistem saraf pusat dan kekerapan penyalahgunaannya 
semakin meningkat semenjak 2005. Mitraginin (MG), substrat/bahan aktif ketum, 
telah dibuktikan boleh menyebabkan ketagihan. Oleh sebab itu, kini dibawah Akta 
Racun 1952, ketum adalah bahan kawalan di mana pemilikan ketum dianggap salah di 
sisi undang-undang. Justeru itu, ujian saringan air kencing diperlukan. Oleh yang 
demikian, objektif utama projek ini adalah untuk membangunkan suatu imunoesei 
untuk mengesan mitraginin dan metabolit-metabolitnya di dalam air kencing manusia. 
Untuk menghasilkan antibodi terhadap mitraginin, ia telah digandingkan kepada 
protein pembawa, albumin serum lembu yang dikationkan (cBSA) melalui tindak 
balas Mannich. Antigen yang disintesis ini disuntikkan ke dalam dua arnab untuk 
mendapatkan antibodi poliklonal terhadap mitraginin. Antibodi-antibodi dikumpulkan 
seminggu selepas imunasi kedua. Enzim konjugat mitraginin-HRP telah disintesis 
sebagai reagen pengesan melalui tindak balas Mannich. Kedua-dua antibodi dan enzim 
konjugat dioptimalkan dalam imunoesei demi pencirian antibodi mitraginin. 
Imunoesei menggunakan antibodi mitraginin dengan enzim konjugat mitraginin-HRP 
membawa nilai IC50 sebanyak 8.38 ng/mL. Kereaktifan-silang antibodi dengan 7α-
hydroxy-7H-mitragynine (82.65%), speciociliatine (63.20%), dan paynantheine 
(54.35%) menggunakan enzim konjugat mitraginin-HRP. Imunoesei yang 
xxxvi 
 
dibangkitkan menunjukkan had pengesanan bernilai 15.05 ng/mL untuk air kencing 
dan had kuantifikasi pada 27.23 ng/mL di mana sampel air kencing cuma dicairkan 10 
kali ganda dengan larutan penampan. Keputusan intra- dan inter-esei yang didapati 
adalah dalam lingkungan 1.50 – 8.05%. Suatu kaedah kromatografi cecair-ionisasi 
elektrospray-spektrometri jisim (LC-ESI-MS/MS) telah dibangunkan dan disahkan 
untuk pengesanan mitraginin dan metabolit-metabolitnya di dalam air kencing 
manusia. Oleh yang demikian, imunoesei yang dibangkitkan ini diberi pengesahan dan 
keputusan yang diperolehi dikaitkan dengan data daripada LC-ESI-MS/MS. Sepuluh 
sampel air kencing positif manusia telah dianalisa dan dikuantifikasikan dengan 
imunoesei yang telah dibangkitkan dan keputusan ini dibandingkan dengan kaedah 
LC-ESI-MS/MS yang menunjukkan korelasi baik dengan bernilai R2 = 0.7426. Data 
yang diperolehi daripada imunoesei ini menunjukkan jumlah kepekatan yang 
diperolehi daripada sampel-sampel air kencing positif ini adalah dalam linkungan 6.62 
– 81.51 µg/mL. Sampel-sampel ini menunjukkan kepekatan mitraginin pada 0.45 – 
9.81 µg/mL, 9-O-DM-MG pada 5.52 – 24.23 µg/mL, dan 16-COOH-MG pada 4.01 – 
14.85 µg/mL apabila dianalisakan dengan LC-ESI-MS/MS. Ini meliputi jumlah 
kepekatan dalam lingkungan 11.00 – 44.35 µg/mL. Kesimpulannya, suatu imunoesei 
telah berjaya dibangunkan dan disahkan untuk kegunaannya dalam pengesanan 
mitraginin dan metabolit-metabolitnya dalam air kencing manusia. Di samping itu, 
kaedah LC-ESI-MS/MS yang telah disahkan sesuai digunakan sebagai kaedah 
pengesahan.  
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DEVELOPMENT OF AN IMMUNOASSAY FOR MITRAGYNINE 
 
ABSTRACT 
 
Kratom is a tropical plant used in traditional medicine for pain relief and to 
treat diarrhea. However, in Malaysia kratom is commonly misused as a recreational 
drug due to its central nervous system stimulatory effect and its frequency of abuse 
has been on the rise since 2005. Mitragynine (MG) an active ingredient in kratom has 
been proven to be addictive. Thus, possession of kratom is now illegal and controlled 
under the Poisons Act 1952. Therefore, a rapid screening urine test needs to be 
developed. For effective enforcement to monitor the kratom abuse, the main objective 
of this project was to develop an immunoassay for the detection of mitragynine 
residues and its metabolites in human urine. To raise anti-mitragynine antibodies, 
mitragynine was conjugated to the carrier protein, cationized-bovine serum albumin 
(cBSA) directly using the Mannich reaction. The synthesized antigen was injected into 
two rabbits to raise polyclonal antibodies against mitragynine. The antibodies were 
harvested a week post the (2nd) booster immunization. Horseradish peroxidase-
mitragynine (HRP-MG) conjugate was synthesized via Mannich reaction and used as 
a tracer. These antibodies and enzyme-conjugate were optimized for antibody 
characterization. The antibody assay using HRP-MG produced an IC50 of 8.38 ng/mL. 
The antibody cross-reacted with 7α-hydroxy-7H-mitragynine (82.65%), 
speciociliatine (63.20%), and paynantheine (54.35%) using HRP-MG. The 
immunoassay developed showed a limit of detection (LoD) of 15.05 ng/mL (ppb) and 
a limit of quantification (LoQ) of 27.23 ng/mL (ppb) in urine whereby the urine 
samples were diluted 10 times with dilution buffer. The variation of intra-day and 
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inter-day assay results ranged from 1.50 – 8.05%. A liquid chromatography tandem 
mass spectrometry (LC-ESI-MS/MS) method was developed and validated for the 
detection of mitragynine and its metabolites in human urine. Therefore, the developed 
immunoassay was validated and its results correlated with the LC-ESI-MS/MS data. 
Ten positive human urine samples were screened and quantified using the developed 
immunoassay method and their results compared with that of the LC-ESI-MS/MS 
method showed good correlation of R2 = 0.7426. Data collected from the immunoassay 
showed positive urine samples with total concentration ranging from 6.62 – 81.51 
µg/mL (ppm). These positive samples analysed with the LC-ESI-MS/MS showed 0.45 
– 9.81 µg/mL (ppm) of mitragynine, 5.52 – 24.23 µg/mL (ppm) of 9-O-DM-MG, and 
4.01 – 14.85 µg/mL (ppm) of 16-COOH-MG thus, giving a total concentration range 
of 11.00 – 44.35 µg/mL (ppm). Therefore, it was concluded that an immunoassay was 
successfully developed and validated for the detection of mitragynine and its 
metabolites in human urine. The validated LC-ESI-MS/MS method was suitable to be 
used as a confirmation method.  
1 
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Mitragyna speciosa 
Mitragyna speciosa (Figure 1.1) is a tropical plant native to many Southeast Asian 
countries, such as Thailand, Malaysia and Myanmar. It is a member of the Rubiaceae 
family and goes by local names such as ‘kratom’, ‘kakuam’, ‘ithang’, and ‘thom’ in 
Thailand; ‘mambog’ in the Philippines; and ‘biak-biak’ and ‘daun ketum’ in Malaysia 
(Houghton et al., 1991). The Malaysian name ‘biak-biak’ aptly refers to the ability of 
this plant to grow wild on different terrain and especially in swampy areas. The kratom 
tree can grow beyond 15.2 meters in height and 4.6 meters in diameter.  
  
Like most plants in nature, kratom also exhibits medicinal properties such as 
antihypertensive, anti-diabetic, improvement of blood circulation, analgesic, 
antipyretic, to counter fatigue, as well as in the treatment of cough and diarrhea 
(Kumarnsit et al., 2006; Assanangkornchai et al., 2007; and Utar et al., 2011). Its uses 
also extended to being a stimulant at low doses, and as an opium substitute at high 
doses, and this has lead to its use for wearing off heroin addiction. The leaves produce 
these narcotic-like effects when smoked, chewed, or drank as a suspension 
(Matsumoto et al., 1997).  
 
Addiction is common among kratom users leading to prolonged sleep with heavy use. 
Chronic users of kratom experience insomnia, anorexia, weight loss, stomach 
distension, nausea, constipation, increased urination, sweating, darkening of the skin 
especially the cheeks, and dryness of the mouth (Kumarnsit et al., 2006; and 
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Chittrakarn et al., 2008). On the other hand, withdrawal symptoms bring about 
aggression, tearfulness, hostility, inability to work, and muscle pain (Chan et al., 
2005). According to Assanangkornchai et al. (2007), men recorded a higher rate of 
kratom consumption compared to women. The majority of them also showed a 
concurrent use of cannabis and amphetamine at some time.  
 
               
  
 
               
 
Figure 1.1 The diagram showing the kratom powder (i), kratom flower (ii), kratom 
extract (iii), and kratom seeds (iv) (adapted from Mitragyna.com, 
2012). 
 
There are two types of kratom differentiated by the colour of the veins of the leaf, i.e. 
red veins (Figure 1.2i) and green veins (Figure 1.2ii). Both types of kratom have 
different effects and are known to be taken simultaneously for better results. The red 
vein kratom is believed to have stronger biological activities especially sedation at low 
doses (Chittrakarn et al., 2008). It is often used for pain relief and detoxing therapies. 
i ii 
iii iv 
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Conversely, green vein kratom with its stimulating and euphoric effect, is often utilized 
as an antidepressant (Kumarnsit et al., 2007).  
 
             
 
Figure 1.2 The diagram showing the red vein kratom (i), and green vein kratom 
(ii) (adapted from Herbal Flame, 2015). 
  
The leaves are consumed either as ground powder or boiled in water. They exert their 
biological effects within 5 to 10 minutes of ingestion and the effects last for 1 to 1.5 
hours depending on the amount consumed (Hassan et al., 2013). Kratom is known to 
have a biphasic effect with initial exhilaration followed by sedation. Chittrakarn et al. 
(2008) have proved that it is more a central nervous system stimulant rather than a 
depressant. Kumarnsit et al. (2007) in his study revealed that kratom demonstrated 
antidepressant activity without spontaneous motor stimulation at doses of 100, 300 and 
500 mg/kg. Moreover, the consumption of 300 mg/kg of aqueous extract in rats 
inhibits ethanol withdrawal-induced behaviours such as rearing, displacement and 
head weaving in a test of induction of ethanol withdrawal and treatment (Kumarnsit et 
al., 2007). Chittrakarn et al. (2008) documented antidiarrheal effect on rat 
gastrointestinal tract using the kratom methanolic extract. Kratom leaves can also be 
used as an antimicrobial as well as antioxidant agent (Parthasarathy et al., 2009). In 
summary, kratom possess anti-inflammatory, antinociceptive, anaesthetic, anti-
i ii 
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malaria, anti-diarrheal, anti-depressant, adrenergic, antioxidant, antimicrobial, and 
antitussive properties.  
 
However, Saidin et al. (2008) showed dose-dependent cytotoxicity in several human 
cancer cell lines using the Mitragyna speciosa alkaloid extract (MSE). The data 
indicated that this cytotoxicity was enhanced in the presence of cytochrome enzyme, 
CYP2E1. A similar result was also observed with mitragynine, a major alkaloid 
constituent in kratom leaves.   
 
1.2 Chemical constituents of Mitragyna speciosa 
More than 40 alkaloids have been isolated from kratom. Alkaloids are nitrogenous 
compounds that exert a bitter taste. Most alkaloids are optically active and some of 
them exhibit curative properties (Ikan, 2013). 
 
The two most abundant types of alkaloids are the indoles (mitragynine, paynantheine 
and speciogynine) and oxyindoles (mitraphylline and speciofoline). Mitragynine is the 
major alkaloid contributing 12 – 66.2% of the total alkaloid extract (Takayama, 2004). 
Paynantheine (8.6%) with a molecular formulae of C23H28N2O4 and a molecular 
weight of 397.0 g/moL, has the same configuration as speciogynine at C20 bearing a 
vinyl group instead of an ethyl group. Speciogynine (6.6%) is the third most abundant 
alkaloid present in kratom. It is a diastereomer of mitragynine which differs in the 
configuration at stereocenter C20. Both paynantheine and speciogynine act as a 
smooth muscle relaxant. Other smooth muscles relaxants also include speciociliatine, 
7α-hydroxy-7H-mitragynine and mitraciliatine. Speciociliatine (0.8%), a C3 
stereoisomer of mitragynine, is a weak opioid agonist. Its potency at the opioid 
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receptor is 13-fold less than mitragynine. Moreover, speciociliatine, speciogynine, and 
paynantheine were shown to inhibit the naloxone-insensitive twitch contraction in rats 
(Takayama, 2004).  
 
The geographical location of kratom results in variation of alkaloid constituents in its 
leaves (Takayama, 2004). It was reported that the major alkaloid, mitragynine, isolated 
from kratom growing in Thailand constitutes 66.2% of total chemical constituent 
compared to 12% with the Malaysian variant. Five identical alkaloids obtained from 
both the Thailand and Malaysia variants include mitragynine, speciogynine, 
speciociliatine, paynantheine, and 7α-hydroxy-7H-mitragynine. In 1975, Hemingway 
et al. discovered three new speciofoline isomers. They were mitrafoline, 
isomitrafoline, and isospeciofoline. Mitrafoline, a non-phenolic 9-
hydroxyrhynchophylline-type alkaloid, has identical chemical behaviour as 
rotundifoline. However, dissimilarity in a number of minor alkaloids found in the 
Malaysia variant differentiates it from the Thailand variant.  
 
Houghton et al. (1991) showed that mitragynaline and corynantheidaline are the major 
alkaloids in very young leaves of kratom in Malaysia. But, mitragynaline is then found 
to be in minute quantities as the leaves mature. Other compounds like mitragynalic 
acid and corynantheidalinic acid remain as minor compounds in the leaves. Houghton 
and Said (1986) also isolated a new yellow coloured alkaloid 3-dehydromitragynine 
that gave rise to yellow colouration skin for kratom users. In 2000, Takayama et al. 
discovered a new corynanthe-type indole alkaloid named as (-)-9-
methoxymitralactonine.  
 
6 
 
Another compound, 9-hydroxycorynantheidine, bears a hydroxyl group at C9 instead 
of a methoxy group. Matsumoto et al. (2006) verified that 9-hydroxycorynantheidine 
was a partial agonist of opioid receptors. The transformation from methoxy group 
(mitragynine) to hydroxy group (9-hydroxycorynantheidine) or to hydrogen 
(corynantheidine) at C9 drastically shifted it from a full agonist to an antagonist of 
opioid receptors (Takayama, 2004). The 9-hydroxycorynantheidine inhibited the 
electrically-induced twitch contraction with a maximum inhibition of 50%, which is 
lower than mitragynine.  
 
Corynantheidine does not show any opioid agonist properties. Its antagonistic effect is 
concentration dependent. It inhibits the effect of morphine via functional antagonism 
of opioid receptors. Mitralactonal has a 9-methoxyindole nucleus. It shows long 
wavelength absorption at UV 496 nm indicating a high degree of unsaturation in the 
molecule (Takayama, 2004). All these unique alkaloids found in kratom (Table 1.1) 
have attracted a lot of researchers to study the chemical and pharmacological potentials 
of this plant such as mitragynine and 7α-hydroxy-7H-mitragynine.  
 
Table 1.1 Table showing the alkaloids found in Mitragyna speciosa. 
 
Alkaloid     Structure 
 
             
                                                                 
 
 
 
Mitragynine  
(3S, 15S, 20S)  
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Table 1.1 Continued. 
 
Alkaloid     Structure 
 
         
      
 
          
      
 
 
 
 
 
 
 
 
 
Speciogynine 
(3S, 15S, 20R) 
Mitraphylline 
Speciofoline 
Paynantheine 
(3S, 15S, 20R)  
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Table 1.1 Continued. 
 
Alkaloid     Structure 
 
 
  
 
  
   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
7α-hydroxy-7H-mitragynine 
Mitraciliatine 
(3R, 15S, 20R) 
Speciociliatine 
(3R, 15S, 20S) 
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Table 1.1 Continued. 
 
Alkaloid     Structure 
 
         
          
 
  
 
 
 
 
  
  
 
 
 
 
 
Mitrafoline 
 
Isospeciofoline 
Mitragynaline 
Isomitrafoline 
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Table 1.1 Continued. 
 
Alkaloid     Structure 
 
 
  
 
  
  
 
 
                     
 
      
       
 
      
        
 
 
 
Corynantheidaline 
Mitragynalic acid 
(-)-9-methoxymitralactonine 
 
3-dehydromitragynine 
Corynantheidalinic acid 
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Table 1.1 Continued. 
 
Alkaloid     Structure 
 
       
 
    
       
 
 
       
 
 
 
1.2.1 Mitragynine  
Mitragynine is the major alkaloid found in kratom. It was first isolated in 1921 and its 
structure fully elucidated in 1964. It has a molecular formula of C23H30N2O4 with a 
molecular weight of 398.50 g/moL. Its melting and boiling points range from 102 – 
106°C and 230 – 240°C respectively. It is soluble in chloroform, alcohol, acetic acid, 
acetone and diethyl ether. It has an UV absorbance at 254 nm (Chee et al., 2008). 
Chemically, it is named 9-methoxycorynantheideine due to the presence of a methoxy 
group at position C9. Compared to the general corynanthe-type indole alkaloids, it is 
Corynantheidine 
Mitralactonal 
9-hydroxycorynantheidine 
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structurally characteristic of the Mitragyna alkaloid. The methoxy group at C9 is the 
key for pharmacophore binding to opioid receptors which controls the intrinsic 
activities on opioid receptors and elicits analgesic activity (Takayama et al., 2002). It 
has an indole structure similar to reserpine, yohimbine, uncaria alkaloid, and other 
tryptamine compounds.  
 
Mitragynine exhibits an uncommonly strong analgesic effect (Thongpradichote et al., 
1998). It is mediated by the µ- and δ- opioid receptors (Takayama et al., 1995). 
Matsumoto et al. (1997) reported that mitragynine appeared to be a psychoactive drug. 
It produced analgesic and antitussive actions comparable to codeine without causing 
emesis or dyspnoea. Due to its structural similarity to codeine and morphine, 
comparison studies were conducted by Watanabe et al. (1997) on the analgesic effect 
of mitragynine on electrically stimulated contractions in the guinea-pig ileum. The 
results showed that analgesic activity by mitragynine was 6-fold less potent than 
morphine. Mitragynine itself can induce antinociceptive activity by acting in the brain 
and partially in the supraspinal opioid systems (Matsumoto et al., 1996). Nevertheless, 
its analgesic qualities were further enhanced when it was used in combination with 
morphine and effectively impaired the development of substance tolerance. 
Furthermore, it also reduced liver toxicity as a result of chronic administration of 
morphine (Fakurazi et al., 2013).  
 
This is in accordance to the claim that kratom consumption results in anorexia and 
weight loss due to the inhibitory effect on gastric acid secretion via opioid receptors. 
Kumarnsit et al. (2006) showed that mitragynine administration resulted in decreased 
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weight gain in rats as well as indirectly lowered blood glucose level because of reduced 
food and water intake.  
 
1.2.2 7α-Hydroxy-7H-mitragynine 
7α-Hydroxy-7H-mitragynine is a terpenoid indole alkaloid with a molecular formula 
of C23H30N2O5 and a molecular mass of 414.50 g/moL. It accounts for 2% of the total 
alkaloid extract. Although it is present in minute amount in the plant, this novel opioid 
agonist is not only 13-fold more potent than morphine with less adverse effects 
(Matsumoto et al., 2004), but it is also 46-fold more potent as an analgesic compared 
to mitragynine. Therefore, 7α-hydroxy-7H-mitragynine is believed to be the most 
pharmacologically active alkaloid from Mitragyna speciosa.  
 
7α-Hydroxy-7H-mitragynine is structurally different from other opioid agonist and it 
exerts analgesia and euphoria in small doses. On the other hand, high doses bring about 
sedation. The hydroxyl group at position C7 enhances pharmacophore binding to µ-
opioid receptors resulting in better oral absorption compared to morphine (Takayama 
et al., 2002; Matsumoto et al., 2004). Thus, 7α-hydroxy-7H-mitragynine is a potential 
candidate for pain management and as an opiate substitute. However, it is most 
effective when used together with other alkaloids in the leaves.  
 
1.3 Abuse of kratom 
Drugs or substance abuse can be defined as drugs or substances consumption without 
approval by medical professionals. Individuals taking drugs for nonmedical purposes 
are not a new phenomenon. Drug abuse leads to social problems such as crime, 
unemployment, and violence. The National Anti-Drug Agency of Malaysia (AADK) 
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documented a total of 300,241 drug users from 1998 to 2006. That was approximately 
1.1% of the Malaysian population (Vicknasingam & Mazlan, 2008). On 11 June 2012, 
the New Straits Times reported that young people aged between 18 and 39 tops the 
drug abuse list. Although kratom is not categorised as a drug, it is utilized in the same 
context as recreational drugs, i.e. heroin, methamphetamine, cannabis, ketamine, and 
ecstasy (MDMA).  
 
The rampant abuse of kratom in Thailand and Malaysia, has forced both governments 
to raise awareness towards kratom (Houghton and Said, 1986) where it is claimed to 
cause addiction. Due to its opium-like effects, possession and ingestion of kratom are 
deemed illegal in both countries (Houghton et al., 1991). Although Thailand has 
banned the usage of kratom since 1943, its use is still rampant as this plant is native to 
the country. Its use is also considered illegal in Australia, Myanmar, Vietnam and 
Denmark. Thus in 2004, mitragynine and kratom have been placed in schedule 9 of 
the Australian National Drugs and Poisons Schedule. Nevertheless, this plant remained 
uncontrolled in other countries like the United States of America and most countries 
in Europe (Chittrakarn et al., 2008).  
 
In 2006, many psychotropic herbal products adulterated with synthetic cannabinoids 
were found to be marketed worldwide rampantly especially through the internet. Their 
appearance in Japan since 2008 prompted Kikura-Hanajiri et al. (2011) to study and 
evaluate them. His survey findings revealed that mitragynine was detected in products 
at 1.2 – 6.3% and 7α-hydroxy-7H-mitragynine ranging from 0.01 – 0.04%. Thus, 
kratom abuse became a foremost issue for concern.  
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Similar issues were seen in a survey on the prevalence of psychoactive drug usage 
among drivers in Thailand (Ingsathit et al., 2009). Studies showed the use of 
mitragynine was increasingly popular and reportedly as one of the most common illicit 
drugs besides cannabis. In addition, a case report that indicated massive overdose of 
kratom could cause intrahepatic cholestasis (Kapp et al., 2011). With its ability to 
produce euphoric effect, relaxation and pain relief similar to that of opium, these 
medicinal properties are due to be abused. Moreover, this plant is indigenous to 
Southeast Asian countries and is cheap to acquire. Consequently, this plant is illegal 
in these countries:  
 
 Australia (placed in schedule 9 of the Australian SUSDP) 
 Denmark  
 Malaysia (mitragynine was listed in the First Schedule and Third Schedule 
(psychotropic substances) of the Poisons Act 1952 of January 2003 and kratom 
was deemed illegal without a government license since August 2006) 
 Myanmar (under section 30(b) of the Narcotic Drugs and Psychotropic 
Substances Law) 
 Thailand (classified as narcotic level 5)  
 Vietnam  
 
In other countries such as US, UK, and Germany, kratom usage is still not regulated. 
In Malaysia, there has been a growing trend among drug addicts who ingest kratom 
leaves to get high when they are unable to acquire their regular supply of cannabis or 
heroin. This kratom abuse has caused considerable concern among the public and law 
enforcement authorities. Its popularity is principally due to its wide availability and 
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low price compared to other illicit drugs. As mitragynine was found to be the major 
alkaloid of kratom, thus it was listed in the First Schedule and Third Schedule 
(psychotropic substances) of the Poisons Act 1952 of January 2003. Under the Act, 
planting the kratom tree is not an offense. However, individuals in possession or 
selling kratom leaves or drinks would be fined a maximum of RM10,000 or served 
four years jail or both (Chan et al., 2005).  
 
Lately, more stringent enforcement and regulation on kratom abuse was implemented. 
According to Malaysian country report, the government is in the final process of 
scheduling kratom under the Dangerous Drug Act 1952 to strengthen control of kratom 
by making its cultivation and trafficking illegal. Under the Dangerous Drug Act 1952, 
it provides mandatory death sentence for drug trafficking offenders (National Anti-
Drugs Agency, Jun 2015).  
 
1.4 Problem statement 
Although kratom toxicity was insignificant and was a potential candidate as an 
alternative to methadone (Lago, 2013), this plant was still abused. This ultimately led 
to addiction. The increase of kratom abuse in Malaysia since 2005 caused many 
problems for the community such as crimes, neglect of family, poor work performance 
and also loss of consciousness. Extensive use of kratom results in prolonged sleep. The 
withdrawal symptoms include hostility, aggression, tearfulness, muscle pain and 
inability to work.  
 
Hence, it is essential to not only control misuse of kratom but also to detect and monitor 
the users. Up till now, many chromatographic methods have been published to detect 
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mitragynine and other related alkaloids qualitatively and/or quantitatively. Although 
chromatographic methods using liquid chromatography (de Moraes et al., 2009; 
Kikura-Hanajiri et al., 2009; Lu et al., 2009; Vuppala et al., 2011; Le et al., 2012; 
Parthasarathy et al., 2013) or gas chromatography (Kaewklum et al., 2005) are able to 
detect and confirm the presence of drugs quantitatively, however, the application of 
these methods are restricted by high analysis cost, and skilled/trained personnel are 
required. Hence, there is a need for the development of an immunoassay which is 
cheap, convenient and easy, rapid to use in screening for the presence of mitragynine 
(the major active alkaloid for kratom) in biological samples. It only requires a small 
amount of sample for analysis, no sample preparation is required, and simultaneous 
analyses of a large number of samples.   
 
The contribution of this research work includes the reduction of kratom abuse by 
effective detection of users and minimization of social problems contributed by drug 
abusers through the development of a locally made ELISA test kit which is currently 
unavailable. 
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1.5 Objectives of study 
The scope of this project encompasses the development of an immunoassay for the 
detection of mitragynine and its metabolites to monitor the kratom abusers. Therefore, 
the objectives of this research involve: 
 
 To modify mitragynine for the use as a specific immunogen. 
 To raise polyclonal antibodies towards mitragynine using the synthesized 
hapten. 
 To synthesize mitragynine enzyme-conjugates for the use as a tracer in enzyme 
immunoassay. 
 To optimize an enzyme immunoassay for the rapid screening of mitragynine 
and its metabolites. 
 To characterize the polyclonal antibodies raised. 
 To develop a validated liquid chromatography-tandem mass spectrometry (LC-
ESI-MS/MS) method for the validation of the developed immunoassay and 
confirmation of mitragynine and its metabolites.  
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CHAPTER 2 
HAPTEN MODIFICATION AND CONJUGATION 
 
2.1 Introduction 
The synthesis of a suitable hapten is critical in antibody production. It determines the 
affinity and the specificity of antibodies produced against the drug. Therefore, this 
chapter discusses the designations of the hapten mitragynine and its modifications as 
the first step to make antigen(s) for raising antibodies. Hapten refers to a small 
molecule e.g. a drug molecule which is too small to be immunogenic. Immunogenic 
molecules are huge molecules that are injected into animals to elicit an immune 
response. All immunogens are antigens but not all antigens are immunogens. Antigens 
are macromolecules which contain antigenic sites and are able to bind with antibodies 
in the immune system. Immunogenic compounds are foreign to the host system, have 
a high molecular weight and chemical complexity (Coico & Sunshine, 2009).  
  
Molecules with a molecular weight of less than 5,000 Daltons (Da) are not considered 
an effective immunogen as they are unable to induce an immune response and produce 
hapten-specific antibodies (Crowther, 1995). This can be solved by coupling small 
molecule haptens to a large carrier protein which is able to stimulate the host immune 
response. Proteins are commonly used as carrier molecules due to their solubility and 
abundance of functional groups for conjugation. These carrier proteins can be keyhole 
limpet haemocyanin (KLH), bovine serum albumin (BSA), human serum albumin 
(HSA), thyroglobulin (THG), gamma globulins, fibrinogen, ovalbumin, synthetic 
polypeptides poly-L-lysine, and polyglutamic acid. The hapten-carrier conjugate can 
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be injected in any experimental animal except the animal of origin of the carrier protein 
itself.  
  
Bovine serum albumin (BSA) is one of the most common protein used as it is cheap, 
physically and chemically stable, easily available, has good solubility, possesses 
numerous lysine residues and amino groups (Dewen et al., 2007). Its molecular weight 
is 67,000 Da and possesses 59 lysine ε-amine groups (only 30 – 35 of lysine ε-amine 
groups are available for conjugation), 1 free cysteine sulfhydryl (with an additional 17 
disulfides buried within its three-dimensional structure), 19 tyrosine phenolate 
residues, and 17 histidine imidazole groups. The presence of abundant carboxylate 
groups in BSA contributes to a nett negative charge with pI value of 5.1. Modification 
of any carrier protein with hydrophobic haptens may result in precipitation due to the 
decrease of hydrophilicity. Therefore, the level of carrier protein modification in the 
conjugation reaction should not be too extensive in order to minimize precipitation 
(Hermanson, 2008).  
 
Cationized-BSA (cBSA) is synthesized through the modification of the carboxylate 
groups of BSA using ethylenediamine. After modification of BSA, the negative 
charges contributed by the native carboxylates are masked and the positive charges 
from the amines are created. Thus, increasing its pI value (pI > 11.0) when compared 
to the native BSA. The higher pI value contributes to better immunogenicity whereby 
its rate of binding to APC is accelerated and consequently produce a quicker immune 
response (Hermanson, 2008).  
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Keyhole limpet haemocyanin (KLH) contains plenty of functional groups for 
conjugation purposes. Its molecular weight is more than 1,000,000 Da with more than 
2,000 amines from lysine residues, over 700 sulfhydryls from cysteine groups, and 
more than 1,900 tyrosines. It is a multi-subunit protein which contains chelated copper 
of non-heme origin. Native KLH is stable and soluble in buffers containing at least 0.9 
M sodium chloride (NaCl). Precipitation and denaturation happen at a concentration 
less than 0.6 M of NaCl. As a result, a high salt condition should be employed when 
multi-subunit KLH is used for conjugation. This is to maintain the solubility of the 
hapten-carrier complex. KLH should not be frozen due to freeze-thaw effect as it may 
cause denaturation. KLH is completely soluble in 50% DMSO and becomes cloudy at 
60%. It precipitates at 67% of DMSO (Hermanson, 2008).  
 
Ovalbumin has a molecular weight of 43,000 Da. It is a phosphoprotein that contains 
N-glycosylation sites with 386 amino acids. It has 20 lysine residues, 14 aspartic acids, 
and 33 glutamic acid groups with a pI value of 4.63. Solubility for ovalbumin in 
DMSO is up to 70%, become cloudy at 75% and precipitates at 80% (Hermanson, 
2008).  
 
Thyroglobulin (THG) is a protein stored in the thyroid gland. It has a molecular weight 
of 660,000 Da with a pI value of 4.7. Usually, THG and ovalbumin are used as non-
relevant carriers in ELISA tests that measure antibody response. It is seldom used as 
carrier in the preparation of immunogens (Hermanson, 2008).  
 
To modify a hapten, some factors need to be taken into consideration. First is the 
structural point of attachment for the hapten to a carrier protein. According to 
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Landsteiner’s Principle, antibody specificity is directed primarily at the part of the 
hapten where it is furthest removed from the functional group that is used to couple to 
a carrier protein. This site of attachment provides steric hindrance by the carrier protein 
that prevents specific recognition of the hapten. Moreover, it is pendent for the hapten 
design to be attached to a carrier protein at a site remote from the chemical or metabolic 
change (Law, 1996).  
 
The second consideration is the functionalization of the hapten. In order to covalently 
attach the hapten to a carrier protein, a suitable functional group must be present in 
hapten to react with complementary functional group on the carrier protein. The 
functional groups can be amino, carboxylic, aldehydes, ketones, thiol, and hydroxyl 
groups. A hapten without the necessary reactive functional groups need to be modified 
by introducing a reactive functional group into the structure prior to conjugation to the 
carrier protein. However, the final chemical structure and stereochemistry should be 
identical with the original hapten (Dewen et al., 2007) to ensure greater antibody 
specificity. 
 
The length of the spacer arm between hapten and carrier protein is important also to 
reduce the steric hindrance effect and allow the hapten to be more easily recognized 
by the circulating lymphocytes (Law, 1996). Long spacers cause the overlapping of 
hapten while short spacers may cause the carrier protein to obstruct the hapten and 
hence produce antibodies with a lack of specificity. According to Bermudez (1975), 
four to six carbon atoms of spacer groups are optimal for antigen-antibody interaction 
and to increase immunogenicity. Additionally, the spacer should be non-polar to avoid 
changes to the distribution of electric density of the hapten. Impurities as a result of 
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hapten synthesis not only reduce assay specificity but are also dangerous to the host 
animals as well. Hence, care must be taken to ensure good hapten quality and purity 
prior to immunization.  
 
Selection of carriers is of utmost importance as different carrier protein induce 
different immune responses and affect antibody quality and quantity. This is because 
the secondary response is determined by the immunogenicity of the carrier proteins. 
Furthermore, the ratio of hapten per molecule of carrier protein has to be taken into 
consideration (Law, 1996) to prevent improper hapten designs that produce low quality 
antibodies.  
 
In this research, mitragynine with a molecular mass of 398.5 g/moL is small and not 
sufficient to induce an immune response on its own. Hence, it must be conjugated to a 
carrier protein before being introduced into experimental animals. Besides, 
mitragynine does not have any suitable functional group for conjugation. Thus, 
introduction of relevant functional groups on mitragynine is needed such as carboxylic 
acid (-COOH), amino (-NH2), hydroxyl (-OH), sulfhydryl group (-SH), aldehyde (-
COH), and ketone (-C=O) groups that are suitable for coupling to a carrier protein. 
The possible sites for modification on mitragynine are shown in Figure 2.1. 
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Figure 2.1 Molecular structure of mitragynine with possible sites for modification 
using various methods. 
 
 
2.2 Aim of study  
The main objective of this chapter is to design and modify the hapten mitragynine by 
introducing reactive functional groups and conjugating it to a carrier protein. 
Modification of carrier proteins is also performed in order to enable better conjugation 
and enhance the binding ratios. Subsequently, the concentrations and coupling ratios 
of successfully synthesized antigens are determined. Moreover, enzyme conjugates are 
also synthesized and used as a detection reagent in an enzyme-linked immunosorbent 
assay (ELISA). 
 
2.3 Materials and instrumentation 
 
Chemicals       Company/ Source 
 
1,2-Dichloroethane      Sigma Aldrich 
        Corporation, USA. 
 
1,4-Butanediol diglycidyl ether ≥ 95%   Sigma Aldrich 
        Corporation, USA. 
 
1-Ethyl-3-(3-dimethylaminopropyl)-    Sigma Aldrich 
carbodiimide hydrochloride      Corporation, USA. 
 
 
